• CAMP4 Therapeutics won Australian TGA clearance to start a Phase 1/2 first-in-human trial of CMP-002 for SYNGAP1-related disorder.
• The milestone triggers eligibility for up to USD 50 million in a second private-placement closing, following about USD 50 million raised in 2025.
• Second closing expected within five business days; issuance up to 32721172 common shares or pre-funded warrants.
• 5AM Ventures joined the investor group backing the second closing; Leerink Partners leads placement agents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 5AM Ventures LLC published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.